Recently, D’Antonio et al. (2016) reported an upregulation of ERBB2 expression in breast cancer patients who harboured similar chromosome 17 kataegis events; these patients also had an extended survival, suggesting prognostic value for kataegis profiling in solid tumours [41]. This evidence concerns the gene ERBB2 and breast carcinoma.